A Collection of Things I Frequently Forget How To Do With Seaborn Scatterplots

 This post is just a placeholder so that people can find the notebook I created to show a few tricks with Seaborn scatterplots.  The notebook, which can be found here, points to this gist.  Note that GitHub can be kind of flakey about displaying Jupyter notebooks.  






Comments

Post a Comment

Popular posts from this blog

We Need Better Benchmarks for Machine Learning in Drug Discovery

Image
Most papers describing new methods for machine learning (ML) in drug discovery report some sort of benchmark comparing their algorithm and/or molecular representation with the current state of the art.  In the past, I’ve written extensively about statistics and how methods should be compared .  In this post, I’d like to focus instead on the datasets we use to benchmark and compare methods.  Many papers I’ve read recently use the MoleculeNet dataset, released by the Pande group at Stanford in 2017, as the “standard” benchmark.   This is a mistake.  In this post, I’d like to use the MoleculeNet dataset to point out flaws in several widely used benchmarks.  Beyond this, I’d like to propose some alternate strategies that could be used to improve benchmarking efforts and help the field to move forward.   To begin, let’s examine the MoleculeNet benchmark, which to date, has been cited more than 1,800 times.   The MoleculeNet collection consists of 16 datasets divided into 4 categories.  Qua
Read more

AI in Drug Discovery 2023 - A Highly Opinionated Literature Review (Part I)

Image
Here’s the first part of my review of some interesting machine learning (ML) papers I read in 2023.  As with the previous editions , this shouldn’t be considered a comprehensive review.  The papers covered here reflect my research interests and biases, and I’ve certainly overlooked areas that others consider vital.  This post is pretty long, so I've split it into three parts, with parts II and III to be posted in the next couple of weeks.    I. Docking, protein structure prediction, and benchmarking II. Large Language Models, active learning, federated learning, generative models, and explainable AI III. Review articles 2023 was a bit of a mixed bag for AI in drug discovery.  Several groups reported that the deep learning methods for protein-ligand docking weren’t quite what they were initially cracked up to be.  AlphaFold2 became pervasive, and people started to investigate, with mixed success, the utility of predicted protein structures.  There were reports of significant advanc
Read more

Getting Real with Molecular Property Prediction

Image
Introduction If you believe everything you read in the popular press, this AI business is easy. Just ask ChatGPT, and the perfect solution magically appears. Unfortunately, that's not the reality. In this post, I'll walk through a predictive modeling example and demonstrate that there are still a lot of subtleties to consider. In addition, I want to show that data is critical to building good machine learning (ML) models. If you don't have the appropriate data, a simple empirical approach may be better than an ML model.  A recent paper from Cheng Fang and coworkers at Biogen presents prospective evaluations of machine learning models on several ADME endpoints.  As part of this evaluation, the Biogen team released a large dataset of measured in vitro assay values for several thousand commercially available compounds.  One component of this dataset is 2,173 solubility values measured at pH 6.8 using chemiluminescent nitrogen detection (CLND), a technique currently consider
Read more